Daily Brief Health Care: Medtronic Plc, WuXi AppTec, Aspira Women's Health and more

In today’s briefing:

Medtronic (MDT US): Q1 Result Exceeds Forecast; FY24 Guidance Raised on Higher Surgery Volumes
Hong Kong CEO & Director Dealings (6 Sept): WuXi AppTec, Peking University, FriendTimes
Aspira Women’s Health, Inc. – Signs Exclusive Agreement with University of Oxford

Medtronic (MDT US): Q1 Result Exceeds Forecast; FY24 Guidance Raised on Higher Surgery Volumes

Medtronic Plc (MDT US) announced better-than-expected Q1FY24 result. Revenue of $7.7B increased 6% on organic basis, ahead of guidance of 4.5%. Each of four segments delivered 6% organic revenue growth.
Adjusted EPS increased 6% YoY to $1.20, ahead of guidance of $1.10–1.12. Outperformance was driven by better-than-expected operational performance and lesser-than-expected unfavorable impact from foreign currency translation.
The company increased FY24 organic revenue growth guidance to 4.5% versus the prior range of 4.0% to 4.5% and adjusted EPS guidance to $5.08–5.16, 7 cent increase at midpoint.

The data in this insight is collated from the “shareholding disclosure” link on the HKEx website.
Often there is a corresponding HKEx announcement on the increase – or decrease – in the shareholding by directors. Or pledging. However, such disclosures are by no means an absolute.
The key stocks mentioned in this regular insight are WuXi AppTec (2359 HK), Peking University Resources (618 HK), and FriendTimes Inc (6820 HK).

Agreement with University of Oxford. On August 31, 2023, Aspira Women’s Health announced that it has entered into a material transfer agreement with the University of Oxford for the procurement of serum samples to be used to verify and validate AWH’s endometriosis blood testing algorithms.
This means that AWH will be able to use the samples to support the launch of EndoCheckSM, its first-generation blood test to aid in the diagnosis of endometriosis.
Verifying the test. This involves taking a test and comparing known samples to run against the test, verifying the test actually works.

💡 Before it’s here, it’s on Smartkarma

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network